LIPIDRESCUE
LIVE

Serial Number

50089187

Owner

ResQ Pharma, Inc.

Attorney

Hillary E. Maynard

Filing Date

Sep 3, 2026

Add to watchlist:

No watchlists yet
View on USPTO

LIPIDRESCUE Trademark

Serial Number: 50089187

LIPIDRESCUE is a trademark filed by ResQ Pharma, Inc. on September 3, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

ResQ Pharma, Inc. (5 trademarks)

242 W. Harrison St., Suite 201
Chicago, IL 60612

Entity Type: 03

Trademark Details

Filing Date

September 3, 2026

Registration Date

Not Registered

Goods & Services

Medical kits consisting primarily of a pharmaceutical preparation in the nature of a lipid emulsion sold inside of a bag, and also including a medical syringe for administering the lipid emulsion, all for use in treating anesthetic and drug toxicity; Medical kits consisting primarily of a pharmaceutical preparation in the nature of a lipid emulsion sold inside of a bag, and also including a medical syringe for administering the lipid emulsion, all for use in resuscitating patients; Medical kits consisting primarily of a pharmaceutical preparation in the nature of a lipid emulsion sold inside of a bag, and also including a medical syringe for administering the lipid emulsion, all for use in treating cardiac arrest due to ischemia and cardiac failure; syringes that are used for administering lipid emulsions in the nature of syringes sold filled with a pharmaceutical, namely, a lipid emulsion for use in treating anesthetic and drug toxicity, treating neurological toxicity, treating cardiac arrest due to ischemia, treating cardiac failure, treating cardiac toxicity, and for resuscitating patients.

Medical services, namely, treating anesthetic toxicity, treating drug overdoses and poisoning, resuscitating patients suffering from the toxic side effects caused by anesthetics and unknown substances, treating cardiac toxins, administering lipid emulsions and other lipid containing substances to patients, and administering lipid emulsions to treat cardiac arrest due to ischemia, cardiac failure, and cardiac toxicity

Filing History

APPLICATION FILING RECEIPT MAILED
Sep 3, 2026 MAFR
NEW APPLICATION ENTERED
Sep 3, 2026 NWAP